K.J. Harrison & Partners Inc Acquires 4,000 Shares of Natera, Inc. (NASDAQ:NTRA)

K.J. Harrison & Partners Inc lifted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 45.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,800 shares of the medical research company's stock after acquiring an additional 4,000 shares during the period. K.J. Harrison & Partners Inc's holdings in Natera were worth $1,810,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in NTRA. LRI Investments LLC acquired a new stake in shares of Natera in the 4th quarter worth $29,000. Rakuten Securities Inc. boosted its holdings in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC acquired a new stake in Natera in the first quarter worth about $32,000. EverSource Wealth Advisors LLC grew its stake in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after acquiring an additional 332 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Performance

NTRA stock opened at $167.96 on Friday. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The firm's fifty day moving average is $158.92 and its 200 day moving average is $158.53. The firm has a market cap of $22.93 billion, a PE ratio of -114.26 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company's quarterly revenue was up 36.5% on a year-over-year basis. During the same period last year, the firm earned ($0.56) EPS. Research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 9,563 shares of the company's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the completion of the transaction, the chief executive officer now owns 212,541 shares in the company, valued at $29,417,799.81. This represents a 4.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total value of $421,440.00. Following the sale, the insider now owns 141,782 shares of the company's stock, valued at approximately $19,917,535.36. This trade represents a 2.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,755 shares of company stock worth $8,898,589 in the last quarter. Corporate insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent analyst reports. UBS Group lifted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Morgan Stanley upped their target price on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Royal Bank Of Canada began coverage on Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target for the company. Finally, Piper Sandler boosted their price target on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.